Kiniksa Pharmaceuticals International Plc (KNSA)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Sanj K. Patel |
| Employees: | 220 |
| Web site: | kiniksa.com |
|
23 OLD BOND STREET, FLOOR 3, LONDON, X0, WIS 4PZ
7814319100
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Kiniksa Pharmaceuticals, Ltd. focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease. KPL-404 is a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation.
Please log in first to see chart